Importantly, however, and in contrast to TNF and CD95L, systemic treatment with TRAIL in vivo killed tumor cells without causing toxicity.20, 21 Thereby, a death ligand with the promising feature of cancer selectivity had been discovered. This evidence concerns the gene FASLG and neoplasm.